What is the projected growth of these companies by the end of 2025

The projected growth of the pharmaceutical companies identified as potentially undervalued and poised for rise by the end of 2025 is as follows:

1. **Merck (MRK)**: Analysts forecast a significant upside for Merck, with an average one-year price target of $112.57, suggesting a potential upside of 42.36% from the current trading price of $79.07. The consensus from 26 brokerage firms places Merck with an average brokerage recommendation of 2.1, classified as "Outperform." GuruFocus estimates project a GF Value for Merck of $121.07 in one year, indicating a potential upside of 53.12% from the current price.
2. **Jazz Pharmaceuticals (JAZZ)**: The average one-year price target for Jazz Pharmaceuticals PLC is set at $189.53, suggesting a substantial upside of 96.83% from the current stock price of $96.30. The consensus from 18 brokerage firms maintains an average brokerage recommendation of 1.8, signifying an "Outperform" status. GuruFocus estimates suggest a potential fair value increase for Jazz over the next year, with a projected GF Value of $163.87, indicating a potential upside of 47.54%.
3. **Addex Therapeutics (ADXN)**: Specific growth projections for Addex Therapeutics are not available, but the company's focus on innovative therapies and the potential for pipeline advancements suggest a possibility of growth as the company continues to develop and commercialize its pharmaceutical products.
4. **Scinai (SCNI)**: Scinai's growth potential is reflected in its projected revenue and profit growth, with a forecasted 24% growth in revenues by the end of 2025. The company's strategic focus and potential for pipeline advancements could contribute to continued growth and valuation appreciation.

It's important to note that while these projections and analyst ratings suggest potential for growth, market dynamics and company performance can change rapidly. Investors should conduct thorough due diligence and consider multiple perspectives before making investment decisions.